Impaired Fas-mediated apoptosis is associated with poor clinical outcomes and cancer chemoresistance. Soluble Fas receptor (sFas), produced by skipping of exon 6, inhibits apoptosis by sequestering Fas ligand. Serum sFas is associated with poor prognosis of non-Hodgkin's lymphomas. We found that the alternative splicing of Fas in lymphomas is tightly regulated by a long-noncoding RNA corresponding to an antisense transcript of Fas (FAS-AS1). Levels of FAS-AS1 correlate inversely with production of sFas, and FAS-AS1 binding to the RBM5 inhibits RBM5-mediated exon 6 skipping. EZH2, often mutated or overexpressed in lymphomas, hyper-methylates the FAS-AS1 promoter and represses the FAS-AS1 expression. EZH2-mediated repression of FAS-AS1 promoter can be released by DZNeP (3-Deazaneplanocin A) or overcome by ectopic expression of FAS-AS1, both of which increase levels of FAS-AS1 and correspondingly decrease expression of sFas. Treatment with Bruton's tyrosine kinase inhibitor or EZH2 knockdown decreases the levels of EZH2, RBM5 and sFas, thereby enhancing Fas-mediated apoptosis. This is the first report showing functional regulation of Fas repression by its antisense RNA. Our results reveal new therapeutic targets in lymphomas and provide a rationale for the use of EZH2 inhibitors or ibrutinib in combination with chemotherapeutic agents that recruit Fas for effective cell killing.
INTRODUCTION
Fas (APO-1, CD95 and TNFRSF6) is a member of the tumor necrosis factor receptor superfamily that has a major role in the extrinsic pathway of apoptosis. Once Fas is activated by its ligand (FasL), a cascade of events leads to apoptosis. 1 Fas receptor is expressed by B-and T-cells, as well as numerous tumor cells and some normal human tissues, yet sensitivity to Fas-mediated apoptosis does not always correlate with Fas expression levels. 2 Defects of the Fas-mediated apoptotic pathway are often associated with lympho-proliferative disorders and autoimmune diseases. [3] [4] [5] Overall survival of individuals with non-Hodgkin's lymphoma (NHL) has improved in recent years with advancements in chemotherapy regimens. 6 However, NHL still demonstrates frequent relapses and a high mortality rate of nearly 30%. 6 One of the likely mechanisms for NHL relapse is the survival and expansion of cells that are resistant to Fas-mediated apoptosis. It has been shown that the cells lacking Fas or cells with defective Fas signaling are resistant to conventional doses of chemotherapy and radiation. [7] [8] [9] [10] Fas levels and its signaling are thus important determinants of the effectiveness of chemotherapy.
Tumor cells can evade apoptosis by several mechanisms; one of them is the release of soluble decoy receptors. The Fas mRNA can be alternatively spliced during mRNA maturation to either include or exclude exon 6 that encodes the trans-membrane domain of Fas receptor. [11] [12] [13] [14] The serum levels of the soluble isoform of the Fas receptor (sFas) are elevated in patients with malignant lymphoma and chronic lymphocytic leukemia (CLL). [15] [16] [17] [18] Soluble Fas blocks apoptosis induced by FasL in vitro, suggesting that production of sFas in lymphoma might be protective 19 and consistent with poor clinical outcomes. 18 The overall survival and disease-free survival rates are significantly lower in lymphoma patients if they express elevated serum sFas levels. 18 The current challenge is to understand regulation of Fas signaling in lymphoma in order to overcome resistance to FasL and chemotherapy. In this study, we investigated the regulation of alternative splicing of Fas pre-mRNA that produces soluble decoy Fas receptor known to be upregulated in lymphoma and a likely source of chemoresistance.
MATERIALS AND METHODS Cells
1 min and by SYBR green method for detection. qRT-PCR data were analyzed by the Step-One software version 2.1.
RNA immunoprecipitation (IP) and immunoblotting (IB)
For precipitation of RNA-protein complexes, 1 Â 10 7 cells were homogenized using the EZ Magna RIP kit per the manufacturer's protocol (Millipore, Billerica, MA, USA). Supernatants were incubated with 1-2 mg of anti-RBM5 (Active motif) or mouse immunoglobulin G (IgG; Invitrogen) for 1 h at 4 1C followed by precipitation with protein A/G agarose (Pierce, Rockford, IL, USA).
IB was performed according to the standard protocols as described previously. 20, 21 Proteins were detected by IB with anti-RBM5, anti-EZH2, anti-histone-3 (Santa Cruz Biotechnology, Dallas, TX, USA), anti-PARP, Figure 1 . For caption see next page.
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anti-cleaved capase-3 and anti-caspase-8 (Cell Signaling Technologies, Danvers, MA, USA) primary antibodies (1:1000 dilution in 5% nonfat milk), followed by the corresponding horseradish peroxidase-conjugated secondary goat anti-mouse or anti-rabbit antibodies (Jackson ImmunoResearch, West Grove, PA, USA). Equal loading was verified by blotting with anti-b-actin-horseradish peroxidase antibody (1:10 000; Sigma Aldrich, Buchs, Switzerland). Visualization was achieved by Supersignal West Pico chemiluminescent substrate (Pierce).
Plasmids and transfections
The pcDNA3 encoding FAS-AS1 (Saf gene) and empty vector were a gift from Dr. Suan Chuang, Taiwan. 22 The pLKO.1 vector control and EZH2 shRNA expressing plasmids were a gift from Dr. Kunal Rai, USA. Plasmid encoding T7-RBM5 and Fas-WT minigene were a gift from Juan Valcarcel, Spain. 12 The transfection of the plasmids was performed using Lipofectamine 2000 (Invitrogen) per the manufacturer's protocol.
Statistical analysis
Experimental data are reported as means ± s.e.m. from three independent experiments, unless otherwise indicated. Differences between groups were calculated using the two-tailed Student's t-test (GraphPad Prism, La Jolla, CA, USA). A P-valueo0.05 was considered statistically significant.
RESULTS
It has been reported previously that the serum levels of sFas are elevated and often associated with the poor outcome of NHLs, thereby suggesting that the level of sFas might be important for the evasion of apoptosis and chemoresistance. 18 A qRT-PCR analysis using specific primers to quantify total Fas mRNA and alternatively spliced Fas mRNA encoding sFas revealed that alternative splicing of Fas pre-mRNA to sFas isoform (skipping of exon 6) is highly upregulated in lymphoma-derived cell lines and tissues ( Figure 1a and Supplementary Figures S1A and B ).
An antisense RNA transcribed from the opposite strand of the intron 1 of the human Fas gene, FAS-AS1, was identified just recently. 22 To test the hypothesis that FAS-AS1 might regulate exon 6 skipping, we determined the expression level of FAS-AS1 long-noncoding RNA (lncRNA) in lymphoma cell lines and tissue samples by qRT-PCR. The levels of FAS-AS1 lncRNA were substantially reduced in primary lymphomas and lymphoma cell lines when compared with healthy donor CD19 þ B lymphocytes (Figure 1b and Supplementary Figure S1C) . We plotted the levels of sFas mRNA and FAS-AS1 lncRNA in lymphoma and other cell lines on x-y graph ( Figure 1c ) and calculated Pearson correlation coefficient (r 2 ¼ À 0.58) that suggested their inverse correlation and thus a possible involvement of FAS-AS1 in regulation of alternative isoform expression as observed in other pairs of gene and antisense mRNA regulatory models. 23 We screened GEO Database Profiles (http://www.ncbi.nlm.nih.gov/geo/) and confirmed the abundance of FAS-AS1 lncRNA in normal tissues.
The gene expression is regulated by various genetic and epigenetic factors, such as hyper-methylation of promoterassociated histone H3. 24 To elucidate the methylation status of the FAS-AS1 promoter, we performed the ChIP-qPCR for trimethylation of lysine 27 of histone H3 (H3K27me3) using the primers spanning the promoter of FAS-AS1 (90752786-90753636) in Z-138 cells, which exhibited clear inverse correlation of sFas and FAS-AS1. The positions of the designed primers were determined from the transcription start site (A; À 400, B; À 900). The specific primer from the FAS-AS1 lncRNA (region C, þ 700) served as the negative control, and the qPCR for a-satellite DNA served as a positive control for the H3K27me3 ChIP. The promoter region of FAS-AS1 was hyper-methylated as compared with the respective IgG control (Figure 1d ). The H3K27me3 was not observed within the non-coding region of FAS-AS1 lncRNA (region C; þ 700), serving as a negative control. However, the positive control, a-satellite DNA, showed tri-methylation confirming the sensitivity of the ChIP experiment. This result suggested that the expression of FAS-AS1 in lymphoma is repressed by promoter hyper-methylation.
The H3K27me3 is carried out by the methyl transferase EZH2. 25 We hypothesized that elevated levels and/or increased activity if EZH2 in lymphoma cells increase H3K27me3 at FAS-AS1 promoter and thus decrease FAS-AS1 expression. We first analyzed gene expression data from 89 lymphoma tissue samples and 34 lymphoma cell lines in the ONCOMINE (cancer microarray database and integrated data-mining platform). 26 We compared mRNA levels of EZH2 in lymphomas to healthy donor's B-lymphocytes from Basso's Lymphoma data set 27 and Baretinna Cancer Cell Line Encyclopedia data set 28 (Figures 1e and f and (e, f ) Z-138 cells were treated with 1 mM DZNeP for 24 h, and total cellular RNA was isolated and subjected to qRT-PCR with primers specific for FAS-AS1 lncRNA (e) (**Po0.001) and sFas mRNA (f ) (**Po0.001).
(g) Lymphoma-derived cell lines were incubated with and without 1 mM DZNeP for 24 h, and concentrations of sFas in the media were determined by ELISA (*Po0.01).
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Supplementary Figure S1D ). This analysis showed that EZH2 mRNA is highly expressed in lymphomas (Burkitt's (BL), diffuse large B-cell (DLBCL), follicular (FL), and mantle cell (MCL)) compared with normal lymph nodes (Supplementary Figure S2A ; www. proteinatlas.org). The micro RNA analysis (August 2010 release of www.microRNA.org) also revealed significantly lower levels of miR26a (Supplementary Figures S2B and C), which is known to negatively regulate the expression of EZH2. 29 These results suggested that the EZH2 expression is substantially upregulated in B-cell lymphomas and may contribute to the hyper methylation of FAS-AS1 promoter.
DZNeP is a methyl transferase inhibitor of H3K27me3 and thus it can de-repress silenced genes. 30 We treated cells with DZNeP to analyze its effect on the levels of EZH2 and total H3K27me3 by IB. DZNeP reduced the levels of H3K27me3 without changing EZH2 levels ( Figure 2a ). To test whether DZNeP inhibits the activity of EZH2, we performed a direct EZH2 activity assay. The transfer of methyl group to the H3 peptide was significantly reduced in the presence of DZNeP (Figure 2b ), confirming that DZNeP effectively ablates EZH2 enzymatic activity. Using ChIP-validated antibody specific to H3K27me3, we confirmed decreased FAS-AS1 promoter methylation in cells treated with DZNeP (Figures 2c and d) .
Our data suggested that FAS-AS1 expression can be modulated by DZNeP. To determine whether the production of sFas is altered by treatment with DZNeP, we analyzed sFas mRNA levels in DZNeP-treated Z-138 cells and the levels of sFas in the media from lymphoma cell lines. Consistent with the results above, treatment with DZNeP showed a profound increase in the levels of FAS-AS1 lncRNA ( Figure 2e ) and modest but significant decrease in sFas mRNA ( Figure 2f ) in Z-138 cells. A more detailed analysis of DZNeP-treated cells showed decreased production of sFas as determined by ELISA (Figure 2g ). We concluded that DZNeP inhibits histone methylation of the FAS-AS1 promoter, leading to altered Fas mRNA processing responsible for the decreased levels of sFas.
We hypothesized that decreased levels of sFas mRNA should translate into elevated levels of membrane-bound Fas (mFas) mRNA and thus mFas protein levels. We analyzed DZNeP-and buffer-treated lymphoma cell lines for surface mFas expression by flow cytometry and confocal microscopy. 20 Both methods showed G r a n t a -5 1 9
G r a n t a -5 1 9 Figure S2D , respectively). These results suggested that the inhibition of EZH2 can indirectly influence the expression of mFas.
To test whether elevated mFas conferred enhanced binding of FasL, we used flow cytometry to evaluate the ability of DZNePand buffer-treated lymphoma cell lines to bind FasL. All tested lymphoma cell lines bound significantly higher levels of FasL upon DZNeP treatment (Figure 3b) . Pretreatment with DZNeP also enhanced the levels of FasL-induced apoptosis (Figure 3c ) in proportion to enhanced surface expression of mFas (Figure 3a ).
An IB analysis of the Fas signaling cascade in the Z-138 cells, which were sensitized to FasL by DZNeP, showed increased processing of pro-caspase-8 in DZNeP pretreated cells compared with buffer-treated controls (Figure 3d ), confirming enhanced proximal Fas signaling at the death-inducing signaling complex.
Thus far, we determined that DZNeP-induced increase in expression of FAS-AS1 shows a reciprocal reduction of sFas and increased mFas expression. In the next step, we tested whether the ectopic expression of FAS-AS1 could regulate skipping of exon 6.
A (Figures 4c and d) . This result suggested that FAS-AS1 lncRNA may stimulate the expression of cell surface mFas and thus also FasL-induced apoptosis.
If FAS-AS1 mediates the apoptosis sensitizing actions of DZNeP, then the cells with knocked down Fas-AS1 will show attenuated Fas-mediated apoptosis with DZNeP. To test this hypothesis, we used siRNA to knock down FAS-AS1 and tested the effects of DZNeP on responses to FasL. As predicted, cells transfected with FAS-AS1 siRNA showed450% reduction of sFas-induced apoptosis compared with vector control (Figure 4e ). As predicted, cells transfected with FAS-AS1 siRNA remained resistant to Fasmediated apoptosis when treated with DZNeP (Figure 4f) , confirming that FAS-AS1 mediated the apoptosis effects of DZNeP (Figures 4f and g ).
To confirm whether the DZNeP-mediated effects are specific to methyl transferase EZH2, we used the shRNAs to knockdown EZH2 in Z-138 cells. The levels of EZH2 were reduced by one of the three tested shRNA clones (Figures 5a and b) . Analysis of RNA confirmed that the reduction in the levels of EZH2 was accompanied by an increase of FAS-AS1 lncRNA and a decrease of sFas. This result suggested that EZH2 may regulate the expression levels of FAS-AS1 in Z-138 cells.
We hypothesized that decreased levels of EZH2 should translate into elevated levels of membrane-bound Fas (mFas) mRNA and thus mFas protein levels. We analyzed EZH2 shRNA and control shRNA-transfected Z-138 cells for surface mFas expression by flow cytometry. The surface mFas levels were elevated in Z-138 cells expressing EZH2 shRNA when compared with vector controls (Figure 5c ). These results confirmed that the inhibition of EZH2 may regulate the levels of FAS-AS1 lncRNA and influence mFas expression. The increased expression of mFas was accompanied by correspondingly enhanced rates of FasL-induced apoptosis in Z-138 cells expressing EZH2 shRNA as compared with vector-transfected cells (Figure 5d ). These results suggested that EZH2 knockdown in FAS-AS1 lncRNA sensitizes B-cell lymphomas to Fas-mediated apoptosis L Sehgal et al cells may stimulate the expression of FAS-AS1 and in turn regulate the cell surface mFas levels and FasL-induced apoptosis. RBM5 (RNA binding motif protein 5) contains structural elements shared by factors involved in pre-mRNA splicing and other aspects of RNA regulation: two RNA recognition motifs (RRM), two zinc fingers, one arginine-serine rich domain, and one glycine patch. 31 Because RBM5 was shown to promote exon 6 skipping, 12 we hypothesized that FAS-AS1 lncRNA might bind directly to RBM5 and alter skipping of exon 6.
We first queried the FAS-AS1 and RBM5 sequences through catRAPID algorithm to estimate their binding propensity. 32 This algorithm predicted that FAS-AS1 lncRNA could bind to two RRM (RRM1 and RRM2) of RBM5 as depicted in the schematic representation (Figure 6a ). To test whether FAS-AS1 lncRNA indeed binds RBM5, we treated Z-138 cells with DZNeP and subjected them to IP using RBM5 antibody followed by RNA extraction and qRT-PCR with FAS-AS1-specific primers. This analysis revealed that RBM5 binding to FAS-AS1 lncRNA is enhanced in DZNeP-treated cells (Figures 6b and c) . This enhanced association of FAS-AS1 with RBM5 was accompanied by decreased association of RBM5 with Fas pre-mRNA (Figure 6d) , suggesting a direct involvement of FAS-AS1 in regulation of exon 6 skipping. Notably, DZNeP did not change the expression levels of either EZH2 or RBM5 (Figure 6b, right panel) . As a specificity control of FAS-AS1 binding to RBM5, we assayed at a possible interaction of other known Fas mRNA splicing protein, HuR, with FAS-AS1 lncRNA by RNA-IP. As predicted, HuR did not interact with FAS-AS1 (Supplementary Figure S3H) .
Taken together, our data suggested that DZNeP increases FAS-AS1 lncRNA, which sequesters RBM5 away from Fas pre-mRNA, and thereby suppresses its alternative splicing into sFas.
To confirm that FAS-AS1 regulate RBM5-mediated splicing of Fas pre-mRNA, we co-transfected HeLa cells with plasmids encoding Fas minigene, FAS-AS1 or RBM5 and evaluated the expression of sFas and mFas mRNAs (Supplementary Figure S3C) . Expression of RBM5 promoted exon skipping and increased the sFas/mFas mRNA ratio. On the other hand, co-transfection with FAS-AS1 significantly decreased this ratio, showing that FAS-AS1 has the dominant effect and confirmed FAS-AS1 interference with RBM5-mediated exon 6 skipping.
We concluded that inhibition of EZH2 activity by DZNeP elevates FAS-AS1 lncRNA, which then sequesters RBM5 from Fas pre-mRNA and thus inhibits skipping of exon 6 and lowers the expression of sFas.
Ibrutinib (PCI-32765) is a selective inhibitor of the Bruton's tyrosine kinase (BTK), 33 the major mediator of B-cell receptor signaling 34 and thus crucial for B-cell development. 35 Ibrutinib was shown to downregulate c-Myc, 36 which inhibits expression of miR-26a, a known negative regulator of EZH2 expression. 29 Thus, we tested whether this BTK-targeting drug affects expression of EZH2 and subsequently interaction of FAS-AS1 with RBM5 and expression of sFas/mFas.
We analyzed total cellular RNA from Z-138 cells treated with ibrutinib or buffer for 40 h by qRT-PCR. The predominant effect was an increased expression of FAS-AS1 lncRNAs followed by upregulation of mFas mRNA and downregulation of sFas. As expected, mRNA levels of both EZH2 and RBM5 were reduced in ibrutinib-treated cells (Figure 7a ). These changes were accompanied by elevated expression of mFas on the surface of FAS-AS1 lncRNA sensitizes B-cell lymphomas to Fas-mediated apoptosis L Sehgal et al ibrutinib-treated cells and the corresponding enhancement of Fas-mediated apoptosis (Figures 7b and c) .
Our results thus suggest that lymphoma cells can be sensitized to Fas-mediated apoptosis through decreasing the expression of EZH2 and RBM5 using BTK inhibitor ibrutinib or by directly targeting the activity of EZH2 by DZNeP.
DISCUSSION
We report here that the long-noncoding antisense RNA to Fas (FAS-AS1) acts as a novel modulator of Fas resistance. Primary B-cell lymphomas and lymphoma-derived cell lines showed elevated expression of sFas relative to healthy B-lymphocytes and concomitantly low expression of FAS-AS1 lncRNA. Our data revealed that the expression of FAS-AS1 is repressed by the EZH2-mediated tri-methylation of H3K27 at its promoter. This repression is released by H3K27me3 inhibitor DZNeP and by selectively downregulating the expression of EZH2. RNA-binding protein RBM5 is known to enhance the skipping of exon 6 during Fas pre-mRNA processing. We found that the FAS-AS1 lncRNA binds to RBM5 and interferes with RBM5-mediated skipping of exon 6. Thus, our data show that RBM5 and EZH2 coordinate the skipping of exon 6, resulting in the production of sFas. BTK inhibitor ibrutinib decreased the expression of EZH2, RBM5 and subsequently sFas levels and increased the expression of FAS-AS1 and mFas. This two-prong process sensitized lymphoma cells to Fas-mediated apoptosis (Figure 8 ). However, we cannot fully exclude additional effects of ibrutinib on apoptotic pathways.
NHL includes lymphoid malignancies ranging from slowly growing indolent lymphomas to aggressive lymphomas such as BL, DLBCL and MCL, each of them characterized by a distinct histopathology and cytogenetic abnormalities. Yet, for over a decade, the standard of care for intermediate grade NHLs has been CHOP therapy regimen (cyclophosphamide, doxorubicin, vincristine and prednisone) with a 5-year survival for patients just above 60%. Recent advancement in targeted therapy with the addition of anti-CD20 antibody rituximab to the CHOP regimen has improved remission rates, but mortality rate still remains relatively high, around 30%. 6 In the current year, 213 companies are developing4300 new lymphoma drugs (Lymphoma Drug Pipeline Update 2013). Targeting overexpressed, histology-specific molecules contributing to lymphoma development or lymphoma cell survival should further improve treatment outcomes.
EZH2, the catalytic subunit of the Polycomb Repressor Complex 2 involved in H3K27 methylation responsible for epigenetic regulation of gene expression, is overexpressed in NHLs and is often associated with disease progression and poor prognosis. 37, 38 EZH2 is required for germinal center formation and its mutants promote lymphoid transformation. 39 Somatic mutations in EZH2 are present in 22% of germinal-center DLBCL and 17% of FLs, which together with the common overexpression of EZH2 in lymphomas make EZH2 a prominent defect in NHL. 40, 41 EZH2 mutants shift its functionality from mono-methylation of H3K27 towards tri-methylation, resembling the effect of EZH2 overexpression, leading to enhanced repression of EZH2 targets. 42, 43 Inhibitors of EZH2 and global H3K27me3 (GSK126, EPZ005687 and DZNeP) were successfully tested in tissue culture and animal models. GSK126 and EPZ005687 effectively inhibited wild-type and mutant EZH2 but had the most potent growthsuppressive effect on EZH2 mutant DLBCL cell lines. 44, 45 DZNeP showed promising results in preclinical models of MCL. 46 Inhibitor FAS-AS1 lncRNA sensitizes B-cell lymphomas to Fas-mediated apoptosis L Sehgal et al of histone methyltransferase EZH2, EPZ-6438 (Epizyme), is being tested in phase I/II clinical trial for DLBCL and FL. DLBCL, MCL and CLL depend on BCR signaling for their survival. [47] [48] [49] BTK is the main mediator of B-cell receptor signaling crucial for the proliferation and survival of B-cells and was proposed as a suitable target for lymphoma therapy. 50, 51 The BTK inhibitor ibrutinib (Janssen Biotech) is being tested in phase III clinical trials for CLL (fast track) and MCL, in phase II trial for DLBCL and multiple myeloma and in phase I trial for FL. Another two BTK inhibitors, CC-292 (Celgene) and ONO4059 (Ono Pharma USA), are being tested in phase I trials for lymphomas and the former also as a maintenance therapy for acute myelogenous leukemia.
Fas death receptor stimulation by FasL-bearing cells is important for the elimination of unwanted or damaged cells, particularly in the lymphoid system. 52, 53 Fas-disabling mutations lead to autoimmune disorders and lymphoma because of the failure to eliminate autoreactive lymphocytes. 54, 55 Fas has evolved to be a key component of responses to chemotherapy, especially genotoxic agents, that elevate expression of Fas and/or FasL to effectively eliminate tumor cells. In DZNeP-treated cells, EZH2 activity is compromised, which promotes the expression of FAS-AS1 lncRNA. FAS-AS1 lncRNA binds and sequesters RBM5 protein preventing RBM5-mediated skipping of exon 6 and ultimately lowers sFas, this leads to sensitization to Fas-mediated apoptosis. Because DZNeP affects EZH2 but not RBM5, the sFas production because of RBM5 still remains, and the effect depends on the residual levels of RBM5 expression. (c) Ibrutinib treatment decreases expression levels of both EZH2 and RBM5 combined with enhanced expression of FAS-AS1, which further results in more pronounced decrease in the levels of sFas corresponding to more efficient interference with crosstalk between EZH2 and RBM5-mediated skipping of exon 6 and thus production of sFas. This translates into sensitization to Fas-mediated apoptosis.
FAS-AS1 lncRNA sensitizes B-cell lymphomas to Fas-mediated apoptosis L Sehgal et al chemotherapy and radiation. [7] [8] [9] [10] One of the mechanisms of Fas resistance is the production of sFas decoy, which is able to sequester FasL away from mFas receptor and thus protects lymphoma cells from Fas-mediated apoptosis. 19 The serum levels of sFas are elevated in patients with malignant lymphoma and CLL. [15] [16] [17] [18] The overall survival and the disease-free survival rates are significantly lower in patients with aggressive NHL and elevated serum sFas levels. 18 Although it was known that sFas is produced by an alternative splicing of Fas pre-mRNA (skipping of exon 6) that involves RBM5, mechanisms regulating this process in cancer cells remained largely unknown. 12 This study reveals cooperation between EZH2-mediated suppression of FAS-AS1 lncRNA and RBM5-mediated exon 6 skipping leading to production of sFas, which is a candidate mechanism for resistance to Fas-mediated apoptosis. Targeting of this mechanism by DZNeP and/or ibrutinib results in the coordinated suppression of sFas and expression of mFas to overcome Fas resistance as illustrated in Figure 8 . Although we cannot exclude a possibility that FAS-AS1 and RBM5 affect expression of other molecules involved in Fas signaling and its regulation, such as cFLIP, 12 our data clearly show that FAS-AS1 sensitizes cells to Fas-mediated apoptosis, at least in part, by regulation of Fas splicing through sequestration of RBM5.
RBM5 is considered a tumor suppressor that is downregulated in a majority of solid tumors. In contrast, expression of RBM5 RNA was reportedly upregulated in 5-fluorouracil-resistant colorectal and breast cancer cells 58 and breast and ovarian cancers. 59 In the other study reported, 59 RBM5 RNA expression was positively correlated with the expression of the HER2 oncogene. We found that the basal level of RBM5 is very low in healthy donor B-cells (also reported in NCBI database), and it is significantly increased in B-cell lymphomas (Supplementary Figures S3D-G) . This suggests that RBM5 may not act as tumor suppressor in B-cell lymphomas and that the regulation of RBM5 may be cell type specific.
We found that a majority of the lymphoma-derived cell lines tested showed increased sensitivity to Fas-mediated apoptosis upon treatment with DZNeP ( Figure 3C ). However, JVM2 (MFI; 3800) and Granta-519 (MFI; 2600) cells, which express high levels of Fas on their surface, were not sensitized to FasL-mediated apoptosis by DZNeP treatment (Figure 3c ). Clearly, Fas signaling can be subjected to regulation through additional mechanisms. 53 Recent reports have revealed that cell surface molecules nucleolin, human herpesvirus-8 K1 and CD44v6/v9, which have their own signaling functions, can also bind and block membrane Fas by interfering with binding of FasL. [60] [61] [62] Though DZNeP may potentially have targets other than EZH2, our analysis using shRNA-mediated downregulation of EZH2 suggests that most of the DZNeP effects on cell death in our experiments are mediated through inhibition of EZH2 ( Figure 5 ). Thus, combining EZH2 inhibitors or BTK inhibitors can prime cells to effectively mediate Fas apoptosis triggered by conventional chemotherapeutic agents.
We conclude that FAS-AS1 lncRNA, expression of which is controlled by EZH2-mediated histone 3methylation, is a novel modulator of the sFas expression. Our finding that FAS-AS1 lncRNA regulates skipping of exon 6 through direct interaction with RBM5 reveals a novel layer of modulation of the Fas death receptor signaling in human lymphomas. Given the altered surface expression of Fas and the often impaired Fas signaling in chemoresistance, we anticipate that addition of EZH2 or BTK inhibitors might reduce chemoresistance by the coordinated suppression of sFas and upregulation of membrane Fas production. Therefore, we look with enthusiasm toward preclinical studies and clinical trials, which should determine whether EZH2 and/or BTK-targeting therapeutics can restore Fas signaling and chemotherapy responses in lymphoma and other malignancies.
